Feline Infectious Peritonitis (FIP) arises from specific mutations of the largely innocuous Feline Enteric Coronavirus (FECV). These mutations allow the virus to escape intestinal epithelial cells and infect macrophages, leading to systemic distribution.
Clinical signs arise weeks, months, or in rare exceptions, years following initial infection. During this early latent/quiescent stage, cats are often fully asymptomatic or exhibit subtle, vague impairments.
Initial clinical presentations typically manifest as generalized systemic disruptions including:
Upper respiratory infection (URI) signs observed during early stages are not directly caused by FIPV. FIPV itself does not cause URI; these signs stem from secondary opportunistic pathogens (e.g., Herpesvirus, Chlamydophila, Mycoplasma) exploiting the cat's early immunologic decline.
Cats typically capitulate to the virus terminally when mucosal and systemic defenses collapse. Advanced stages are characterized by severe, profound immunocompromise. Loss of systemic cell-mediated immunity at this juncture is extremely difficult to reverse, explaining why recovery is unachievable without definitive antiviral intervention.
The type and severity of clinical signs vary based on where infected macrophages migrate and the type of vascular or parenchymal inflammation that follows.
Characterized by Arthus-type immune-complex damage to small blood vessels (vasculitis), resulting in severe leakage of serum protein and high-protein, mucinous, yellow-tinged fluid into body cavities.
*Note: Primary Ocular and Central Nervous System (CNS) involvement is relatively rare in pure wet FIP (found in only ~9% of total cases).
Characterized by localized, chronic pyogranulomatous lesions (mass-like infiltrations of neutrophils, macrophages, and lymphocytes) causing tissue necrosis and parenchymal organ dysfunction. Diffuse effusions are absent.
*Crucial Presentation Rule: Neurological and/or Ocular disease acts as the primary presenting clinical sign in 70% of cats with dry FIP.
The blood-to-brain and blood-to-eye barriers drastically affect both how the disease develops and how it reacts to medication.
The blood-to-brain barrier in healthy felines excludes approximately 80% of systemic drugs, while the blood-to-eye barrier excludes roughly 70%. For instance, if a standard dose of GS-441524 yields an effective blood plasma baseline of 10 µM, the resulting levels in cerebrospinal fluid (CSF) drop to 2 µM, and aqueous humor levels drop to 3 µM.
These barriers create an evolutionary paradox. While protecting organs from external toxins, they also block the entry of systemic antibodies and immune lymphocytes. When FIPV crosses into the brain, spine, or uveal tract, it becomes shielded from the host's immune system, leading to standalone neurological/ocular disease forms.
Inflammation isolated within privileged sites like the CNS is less likely to evoke a system-wide inflammatory response. Consequently, cats presenting with primary neurological FIP (or those experiencing a localized relapse) often show completely normal CBC and chemistry panels, with zero elevation in globulins or drops in albumin ratios.
A definitive diagnosis is reached by compiling signalment (cats under 3-5 years old from catteries, shelters, or multi-cat fosters), physical histories, and specific laboratory abnormalities.
| Lab Parameter | Pathological FIP Trend & Mechanics | Target Thresholds & Healthy Corrections |
|---|---|---|
| RBC / HCT / HGB | Low values indicate systemic inflammatory non-regenerative anemia or red blood cell destruction. | Must normalize. An HCT value < 15% is critical/dangerous. Target HCT is > 24% for treatment cessation. |
| WBC & Neutrophils | Leukocytosis accompanied by high absolute neutrophils signals active pyogranulomatous tissue inflammation. | Initial leukophilia must drop back to established baseline ranges within the first 2 weeks of therapy. |
| Lymphocytes | Low absolute lymphocyte counts show a suppressed or exhausted cell-mediated immune response. | Must rise. Lymphocytosis (high lymphocytes) during therapy is a sign of healthy immune activation and can be safely ignored. |
| Globulin | Severely elevated. Acts as a core marker of the immune system's hyper-inflammatory response. | Must drop. Mild, stable hyperglobulinemia at Day 84 does not correlate with an increased risk of relapse if the cat is clinically well. |
| Albumin | Severely decreased. Albumin leaks out of damaged, inflamed blood vessels into effusions. | Must rise continuously throughout treatment as vascular linings heal. |
| A/G Ratio | Low A/G ratio (typically < 0.6) due to the combination of rising globulins and falling albumin. | A target ratio of 0.7 or higher is preferred. A low ratio is less concerning if globulins are normal and albumin is low-normal. |
Two primary classes of small-molecule viral inhibitors are effective against FIP: RNA synthesis inhibitors (Nucleoside analogs) and Viral Protease inhibitors. Protease inhibitors (GC376, Nirmatrelvir) do not easily cross the blood-brain or blood-eye barriers and are not advised for neurological/ocular cases.
Standard primary therapeutic baseline is a minimum of 84 continuous days. Subcutaneous (SC) injection is twice as bioavailable as oral administration (oral absorption is < 50%, requiring double the dose).
Dosing Guidelines & Adjustments: Doses must be adjusted weekly to account for weight gain. Failure to gain weight is an unfavorable clinical indicator. Any required dose escalation should increase by +2 to +5 mg/kg daily, holding the new tier for a minimum of 4 weeks (extending the 84-day total if necessary).
A cytidine nucleoside analog with a different resistance profile than GS-441524. It is primarily reserved for cases with established GS-441524 drug resistance or neurological relapses after high-dose GS therapy.
*Cautionary Note: Molnupiravir exhibits cellular cytotoxicity at higher thresholds. Complete Blood Counts (CBC) must be monitored closely for bone marrow toxicity.
Expected clinical improvements and hematological adjustments during the 84-day antiviral timeline:
Systemic FIP-induced fever breaks. Initial shifts in alertness, base energy, and appetite manifest in early responding patients. Note: Effusions may transiently increase during the first few days.
Visible response to therapy is noted in a majority of cats. Ocular cloudiness begins clearing and neurological deficits (like paresis) show initial improvement.
Thoracic fluids and associated dyspnea (labored breathing) are typically resolved by this point.
Ascites and visible abdominal fluid distension begin to decrease significantly. Active ocular disease signs are fully resolved in most cases.
Abdominal fluid absorption is complete. Initial inflammatory leukocytosis (high neutrophils) drops back to normal limits. Globulins can show a transient peak around Week 3 as fluid shifts occur.
Packed Cell Volume (PCV) and Red Blood Cell metrics return to healthy baselines after a brief dip in Week 2. Albumin steadily rises and globulins drop, bringing the A/G ratio closer to 1.0. At weeks 8-10, an unexpected surge in vitality occurs, indicating the re-establishment of the cat's own cell-mediated immunity.
Cats that go without food for even a few days can rapidly develop fatal Hepatic Lipidosis (Fatty Liver) as body fat overwhelms the liver. To avoid this:
Surgical procedures represent an immunologic stressor. Intact status is also stressful, meaning surgeries may be considered under strict parameters:
Perform surgery either **2 weeks prior to completing the 84-day treatment** (extending treatment for 2 weeks post-op to monitor for stress induced spikes) OR wait at least **6 weeks into the post-treatment observation phase** to pass the highest risk relapse window. Full blood panels must be normal before surgery. Because FIP induces cardiac stress and anemia, a **Cardiopet proBNP test must be performed on the day of anesthesia** to verify safety.
Injection Sores: Developing necrotizing skin scabs or sores is common with acidic GS injections. Shave the surrounding hair with a 40 blade and apply non-prescription topical antiseptic sprays. Keep the body covered using recovery suits or baby onesies.
Vaccinations: Follow ISFM/WSAVA rules. Vaccines can be administered normally if the cat is clinically stable. Consider a third booster dose after treatment ends to ensure protection.
Flea & Worm Treatments: Standard flea preventatives (Frontline, Revolution) are safe, but can cause temporary neurological side effects that may be confused with neurological FIP. Avoid over-the-counter brands like Hartz. For deworming, Drontal, Pyrantel, and Milbemax are highly recommended.
Treat the cat, not the bloodwork! Evaluating readiness for cessation at Day 84 requires analyzing the complete clinical picture. Do not extend treatment based purely on a single slightly anomalous lab value (such as mild hyperglobulinemia) if the cat has zero clinical signs, normal energy, excellent weight gain, and no ocular/CNS deficits. Conversely, normal bloodwork should not override lingering clinical signs or drug resistance, which require immediate dose escalations (+2 to +5 mg/kg) or switching to alternative therapies.
COPYRIGHT © CUREFIPV. ALL RIGHTS RESERVED.